×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ACTU – actuate therapeutics, inc. - common stock (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ACTU
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/12
09:00 am
actu
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI
Low
Report
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI
1/12
08:45 am
actu
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI
Medium
Report
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI
1/6
08:45 am
actu
Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers
Medium
Report
Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers
12/30
04:09 pm
actu
Actuate Therapeutics (NASDAQ:ACTU) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Actuate Therapeutics (NASDAQ:ACTU) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
12/24
07:01 pm
actu
Actuate Therapeutics, Inc. (ACTU) Upgraded to Buy: What Does It Mean for the Stock? [Yahoo! Finance]
Low
Report
Actuate Therapeutics, Inc. (ACTU) Upgraded to Buy: What Does It Mean for the Stock? [Yahoo! Finance]
12/23
04:09 pm
actu
Actuate Therapeutics (NASDAQ:ACTU) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Actuate Therapeutics (NASDAQ:ACTU) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
12/18
07:02 pm
actu
Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026 [Yahoo! Finance]
Low
Report
Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026 [Yahoo! Finance]
12/18
08:45 am
actu
Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026
Low
Report
Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026
Date
Time
Symbol
Company Name
Action
%Chg
11/13/2025
04:00 pm
actu
actuate therapeutics, inc. - common stock
BEAT
Report
1.1%
actuate therapeutics, inc. - common stock
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/12
04:00 pm
actu
Form 8-K ACTUATE THERAPEUTICS, For: Jan 12
Medium
Report
Form 8-K ACTUATE THERAPEUTICS, For: Jan 12
1/7
12:46 pm
actu
Form 4 ACTUATE THERAPEUTICS, For: Jan 05 Filed by: THOMSON TODD S
Medium
Report
Form 4 ACTUATE THERAPEUTICS, For: Jan 05 Filed by: THOMSON TODD S
12/17
12:26 pm
actu
Form SCHEDULE 13G ACTUATE THERAPEUTICS, Filed by: Voss Capital, LP
Low
Report
Form SCHEDULE 13G ACTUATE THERAPEUTICS, Filed by: Voss Capital, LP
12/11
04:23 pm
actu
Form 144 ACTUATE THERAPEUTICS, Filed by: Kairos Venture Partners II, L.P.
Low
Report
Form 144 ACTUATE THERAPEUTICS, Filed by: Kairos Venture Partners II, L.P.
11/28
05:22 pm
actu
Form 8-K ACTUATE THERAPEUTICS, For: Nov 28
Medium
Report
Form 8-K ACTUATE THERAPEUTICS, For: Nov 28
11/28
05:20 pm
actu
Form 424B5 ACTUATE THERAPEUTICS,
Medium
Report
Form 424B5 ACTUATE THERAPEUTICS,
11/21
04:31 pm
actu
Form 8-K ACTUATE THERAPEUTICS, For: Nov 21
Low
Report
Form 8-K ACTUATE THERAPEUTICS, For: Nov 21
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: